HomeCompareTNPH vs EQR

TNPH vs EQR: Dividend Comparison 2026

TNPH yields 19230.77% · EQR yields 4.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TNPH wins by $35559072563224756224.00M in total portfolio value
10 years
TNPH
TNPH
● Live price
19230.77%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$35559072563224756224.00M
Annual income
$35,199,015,251,958,400,000,000,000.00
Full TNPH calculator →
EQR
EQR
● Live price
4.73%
Share price
$58.58
Annual div
$2.77
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.5K
Annual income
$3,819.61
Full EQR calculator →

Portfolio growth — TNPH vs EQR

📍 TNPH pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTNPHEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TNPH + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TNPH pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TNPH
Annual income on $10K today (after 15% tax)
$1,634,615.38/yr
After 10yr DRIP, annual income (after tax)
$29,919,162,964,164,640,000,000,000.00/yr
EQR
Annual income on $10K today (after 15% tax)
$401.93/yr
After 10yr DRIP, annual income (after tax)
$3,246.67/yr
At 15% tax rate, TNPH beats the other by $29,919,162,964,164,640,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TNPH + EQR for your $10,000?

TNPH: 50%EQR: 50%
100% EQR50/50100% TNPH
Portfolio after 10yr
$17779536281612378112.00M
Annual income
$17,599,507,625,979,200,000,000,000.00/yr
Blended yield
98.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

TNPH
No analyst data
Altman Z
-1881.9
Piotroski
0/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+20.1% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TNPH buys
0
EQR buys
0
No recent congressional trades found for TNPH or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTNPHEQR
Forward yield19230.77%4.73%
Annual dividend / share$2.00$2.77
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$35559072563224756224.00M$40.5K
Annual income after 10y$35,199,015,251,958,400,000,000,000.00$3,819.61
Total dividends collected$35535307211105599488.00M$16.9K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: TNPH vs EQR ($10,000, DRIP)

YearTNPH PortfolioTNPH Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$1,933,777$1,923,076.92$11,248$547.57+$1.92MTNPH
2$349,620,709$347,551,567.77$12,701$666.53+$349.61MTNPH
3$59,099,530,219$58,725,436,060.68$14,405$814.59+$59099.52MTNPH
4$9,340,702,082,592$9,277,465,585,257.05$16,413$999.84+$9340702.07MTNPH
5$1,380,374,723,530,610$1,370,380,172,302,236.20$18,795$1,232.92+$1380374723.51MTNPH
6$190,743,943,336,084,320$189,266,942,381,906,560.00$21,639$1,527.95+$190743943336.06MTNPH
7$24,646,546,669,772,927,000$24,442,450,650,403,320,000.00$25,057$1,903.80+$24646546669772.90MTNPH
8$2,978,031,531,272,736,000,000$2,951,659,726,336,079,400,000.00$29,197$2,385.87+$2978031531272736.00MTNPH
9$336,502,160,062,018,500,000,000$333,315,666,323,556,700,000,000.00$34,250$3,008.70+$336502160062018496.00MTNPH
10$35,559,072,563,224,757,000,000,000$35,199,015,251,958,400,000,000,000.00$40,467$3,819.61+$35559072563224756224.00MTNPH

TNPH vs EQR: Complete Analysis 2026

TNPHStock

Tian'an Pharmaceutical Co., Ltd. develops, manufactures, and sells traditional Chinese herbal medicines, including pallets, hard capsules, and soft ointments for the treatment and prevention of diseases in China. It also engages in the research and development of biology goods and health care products. The company's pharmaceutical and nutraceutical products include Compound Ginseng capsule, a Chinese medicine preparation that is used to cure and treat prostate gland proliferation; Nizhuanle Yin granule, a Chinese medicine preparation that treats the decomposition or inflammation of the stomach's mucous membrane; and Tianan soft capsule, which is used to adjust high amounts of fat in the blood stream, improve blood vessel ventilation, and soften blood vessels. Its products also include Tianan Pain Relief Capsule, a Chinese medicine preparation, which is under development to cure pain in joints, headache, pain from muscle injury, cancer, and gynecological disorders, as well as general pain. Tian' An Pharmaceutical sells its products to independent distributors, who sell products to pharmacies and drugstores, and hospitals. The company was founded in 2003 and is based in Xi'an, China.

Full TNPH Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this TNPH vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TNPH vs SCHDTNPH vs JEPITNPH vs OTNPH vs KOTNPH vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.